Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET Centre. The event offered a rich program—from tracer development to clinical applications, total‑body PET breakthroughs, and AI‑driven imaging strategies.
The dynamic exchange between seasoned experts, technologists, and early‑career researchers made it clear: innovation in nuclear medicine is accelerating.
Such forums go beyond technical curiosity: they are instrumental in shaping next‑generation diagnostics and refining trial design. Axcellant is energized by the practical insights gained and is already exploring how to integrate them into imaging‑based clinical research services.
We are committed to deepening our knowledge and strengthening our expertise in precision imaging, enabling us to continue delivering smarter, more effective trial solutions.
The EU is moving forward with key upgrades to its medical device and diagnostics regulations, specifically under the Medical Device…
Gene therapies now account for most ATMP clinical trials, with a balanced distribution between in vivo and ex vivo approaches.…
Academic medical centers in the US are voicing concern over reduced funding from the National Institutes of Health (NIH). While…
Copyright @ 2025 Axcellant